目的 基于网络药理学方法研究枸杞子治疗代谢相关脂肪性肝病（MAFLD，曾用名非酒精性脂肪肝）主要活性成分的作用靶点及机制。方法 通过中药系统药理学数据库（TCMSP）获取枸杞子的活性成分，设定口服生物利用度（OB）≥30%和类药性（DL）≥0.18，并筛选出枸杞子作用靶点，构建成分-靶点网络。通过GenCards数据库筛选出枸杞子治疗MAFLD的潜在作用靶点，利用Cytoscape软件构建疾病-成分-靶点可视化网络图，进行基因本体论（GO）功能分析和京都基因和基因组百科全书（KEGG）通路富集分析。结果 获得枸杞子活性成分45个，MAFLD差异基因1 656个，交集靶点87个，涉及60条通路，可能通过AKT1、IL6、IL1B等关键靶蛋白，参与DNA结合转录激活因子活性表达、RNA聚合酶Ⅱ特异性转录、肽链内切酶活性等生物学过程，枸杞子可能通过作用于IL-17信号通路、AGE-RAGE信号通路、MAFLD信号通路等发挥治疗MAFLD的作用。结论 枸杞子通过多成分、多靶点、多通路治疗MAFLD。

Objective To explore the target and mechanism of Lycium barbarum in treatment of metabolic related fatty liver disease (non-alcoholic fatty liver disease) based on network pharmacology. Methods The chemical components and targets of Lycium barbarum were obtained from TCMSP databases, and the component-target network was constructed. GenCards databases were used to screen out the potential target of Lycium barbarum for treatment of metabolic related fatty liver disease. Cytoscape software was used to construct the network map of disease-component-target, and further analyze the gene GO function and KEGG pathway enrichment. Results Total 45 active components, 1 656 MAFLD differential genes and 87 intersecting targets were obtained from Lycium barbarum, involving 60 pathways. It may participate in biological processes such as active expression of DNA binding transcription activator, specific transcription of RNA polymerase II and endopeptidase activity through key target proteins such as AKT1, IL6 and IL1B. Lycium barbarum may act on IL-17 signal pathway, AGE-RAGE signal pathway MAFLD signaling pathway plays a role in the treatment of MAFLD. Conclusion Lycium barbarum can treat MAFLD through multi-component, multi-target and multi-channel.

R285